https://doi.org/10.55788/39f2e3d6
PCS is characterised by the persistence of symptoms for more than 3 months or the post-acute onset of symptoms, and/or the deterioration of pre-existing comorbidities [1]. “There is however no efficient scoring tool to diagnose PCS and to stratify the severity of the disease,” according to Prof. Thomas Bahmer (University of Kiel, Germany) [2]. The COVIDOM population-based cohort study aimed to develop a PCS scoring tool [2,3].
In total, 667 patients with PCR-confirmed SARS-CoV-2 infections were included in the training cohort, and 459 and 316 patients were included in 2 validation cohorts. Standardised interviews and on-site examinations 6 and 12 months post-infection were conducted to gather information on symptoms of PCS. Based on 12 long-term symptom complexes, such as fatigue, cough/wheezing, neurological ailments, and joint and muscle pain, the authors designed a PCS scoring tool with weighted PCS scores for different symptoms (see Table).
Table: Weighted post-COVID syndrome scoring tool [2]
Notably, higher scores on the PCS validation scoring tool were related to lower health-related quality-of-life scores, as was assessed by the EQ-5D-5L-VAS/-index (P<0.001), increased blood inflammatory markers (P<0.01), and decreased lung function (P<0.01). The number of acute symptoms and personal resilience, as determined by the Brief resilience scale, were predictive of higher PCS scores 9‒12 months after the acute infection.
Prof. Bahmer emphasised that this easy-to-use tool may be used to diagnose PCS, evaluate the disease burden of patients, and may serve as a clinical endpoint in future trials.
- Nalbandian A, et al. Nat Med. 2021;27(4):601‒
- Bahmer T, et al. Severity score-based study of predictors and clinical correlates of Post-COVID Syndrome (PCS) in Germany. Long COVID and rehabilitation, ERS International Congress 2022, Barcelona, Spain, 4‒6 September.
- Bahmer T, et al. EClinicalMedicine. 2022;51:101549.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Letter from the Editor Next Article
Accurate voice-based COVID-19 diagnostic test in development »
« Letter from the Editor Next Article
Accurate voice-based COVID-19 diagnostic test in development »
Table of Contents: ERS 2022
Featured articles
Letter from the Editor
COVID-19: What Is New?
Does vilobelimab reduce mortality in severe COVID-19?
Awake proning not positive in COVID-19
Favipiravir may help patients over 60 years with COVID-19 to recover
Inhaled agent under investigation for COVID-19
Accurate voice-based COVID-19 diagnostic test in development
Novel scoring tool for post-COVID syndrome aids clinicians and researchers
COPD: Therapies and Innovations
Icenticaftor achieves results on top of triple inhalation therapy in COPD
STARR2: A new approach for treating COPD exacerbations
COPD medication not effective in symptomatic smokers with preserved spirometry
Do digital tools improve physical activity in COPD?
Hyperpolarised gas MRI ready for clinical use
All About Asthma
Tezepelumab in asthma: mucus plugging down, lung function up
Digital asthma intervention improves health and reduces costs
Digitally enhanced therapy lowers treatment burden and costs in severe asthma
Mepolizumab beneficial for patients with severe eosinophilic asthma
Progress in Paediatrics
Antibiotics cause increased risk of wheezing in severe RSV bronchiolitis
Inhaled corticosteroids useful in preterms with decreased lung function
Fish oil or vitamin D during pregnancy can prevent croup
Encouraging results of nintedanib in children with fibrosing ILD
Focus on Interventional Pulmonology
Head-to-head: lung volume reduction surgery vs endobronchial valves
Durable effect of endobronchial valves in severe emphysema
Cone beam CT-guided ENB improves detection of pulmonary nodules
Confirmatory mediastinoscopy not needed in resectable NSCLC
Sleep and Breathing Disorders
In the spotlight: Cancer trends in obstructive sleep apnoea
Impact of CPAP on cardiac endpoints in OSA
Sustained hypoxaemia predicts unprovoked VTE in OSA
CPAP therapy in the prevention of cardiovascular risk in patients with OSA
Other Remarkable Research
Excellent results for high-flow nasal cannula oxygen therapy in acute respiratory failure
Antifibrotic therapy may slow down FVC decline in RAILD
Intravenous N-acetylcysteine performs well in hospitalised patients
Men and women respond differently to diesel exhaust
New trends in cystic lung diseases
Related Articles
October 30, 2022
Inhaled agent under investigation for COVID-19
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com